Management of Pulmonary Tuberculosis

Standard Treatment Regimen for Drug-Susceptible PTB

The American College of Chest Physicians recommends a 6-month regimen for pulmonary tuberculosis, consisting of an initial intensive phase of 2 months with four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) followed by a 4-month continuation phase with isoniazid and rifampin 1, 2
The World Health Organization suggests that four-drug therapy is mandatory, with isoniazid (5 mg/kg daily, max 300 mg), rifampin (10 mg/kg daily), pyrazinamide (35 mg/kg daily for patients <50 kg; 2.0 g daily for patients >50 kg), and ethambutol (15 mg/kg daily) 1, 2
Ethambutol can be discontinued once drug susceptibility testing confirms full susceptibility to isoniazid and rifampin, typically after 2 months when results return 3, 1

The Centers for Disease Control and Prevention recommend extending the continuation phase to 7 months (total 9 months of treatment) in three specific situations: cavitary pulmonary tuberculosis on initial chest radiograph AND positive sputum culture at completion of 2 months of treatment, initial treatment phase did not include pyrazinamide, and HIV-positive patients with CD4+ counts <100 cells/mm³ 3, 1, 2

The American Thoracic Society recommends obtaining sputum cultures monthly until two consecutive negative cultures are documented 2
Patients must demonstrate sputum conversion (culture negativity) within 3 months of treatment initiation 2

The World Health Organization suggests performing drug susceptibility testing on all initial isolates before starting treatment to confirm susceptibility to at least isoniazid, rifampin, pyrazinamide, and ethambutol 3, 2

The American College of Chest Physicians recommends using rifampin, ethambutol, pyrazinamide, and a fluoroquinolone for 6 months for isoniazid-resistant TB (with rifampin susceptibility) 1

The World Health Organization defines MDR-TB as resistance to at least isoniazid AND rifampin 2, 4
The Centers for Disease Control and Prevention recommend using the 6-month BPaLM regimen: bedaquiline, pretomanid, linezolid, and moxifloxacin for 26 weeks for eligible MDR-TB patients 2, 4

The American College of Chest Physicians recommends using the same standard 6-month regimen for HIV-positive patients, but consider extending treatment to at least 9 months and at least 6 months after documented culture conversion 2
HIV testing should be performed for all TB patients within 2 months of TB diagnosis 1

The American Thoracic Society recommends that all first-line drugs (rifampin, isoniazid, ethambutol, pyrazinamide) can be used during pregnancy 5
Streptomycin is contraindicated due to fetal ototoxicity 5

The American Diabetes Association recommends using the same standard regimen as in non-diabetic patients 5
Rifampin reduces the efficacy of sulfonylureas—doses of oral hypoglycemic agents may need to be increased 5, 2

The American Association for the Study of Liver Diseases recommends that in stable liver disease with normal liver enzymes, all anti-tuberculous drugs may be used but frequent monitoring of liver function tests is required 5
Baseline and regular monitoring of liver function is required in patients with chronic liver disease, alcoholism, chronic active hepatitis, cirrhosis, and hepatitis B or C antigen positivity 5

The American Academy of Pediatrics recommends using rifampin and isoniazid for 6 months, supplemented by pyrazinamide for the first 2 months for respiratory tuberculosis including hilar adenopathy 5
Ethambutol should be included in the first 2 months if criteria for a fourth drug apply (same as adults) 5

The American College of Chest Physicians recommends not relying on clinical improvement alone—bacteriologic confirmation of cure is essential 2
Do not treat recurrent TB with the same regimen that failed previously—this guarantees further resistance 2
Never add a single drug to a failing regimen; always add at least two new drugs 4
Implement DOT for all recurrent cases, as treatment failure is most commonly due to non-compliance 4